Payment overview · 2025
General Payments
$201.63
12 reported records · 9 companies
Healthcare provider profile · identity verified
Nicole M Patterson
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CAMBRIDGE CITY, IN · NPI 1871139014
Verified facts
What the public records show
CMS Open Payments records show Nicole M Patterson received $201.63 in general payments during 2025 across 12 reported records.
Esperion Therapeutics, Inc. accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.52 | 31.0% | 4 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $23.96 | 11.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.93 | 9.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.73 | 9.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.13 | 8.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.58 | 7.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.16 | 7.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.86 | 7.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.76 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $201.63 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $62.52 | 4 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 411 | 54 |
| Omeprazole | Omeprazole | 276 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 230 | 34 |
| Gabapentin | Gabapentin | 222 | 37 |
| Lisinopril | Lisinopril | 213 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 142 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 45 |
| Metformin Hcl | Metformin Hcl | 113 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 16 |
| Montelukast Sodium | Montelukast Sodium | 102 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 30 |
| Simvastatin | Simvastatin | 91 | 25 |
| Ozempic | Semaglutide | 84 | 14 |
| Meloxicam | Meloxicam | 79 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 12 |
| Furosemide | Furosemide | 73 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 20 |
| Potassium Chloride | Potassium Chloride | 68 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 11 |
| Alendronate Sodium | Alendronate Sodium | 66 | 22 |
| Losartan Potassium | Losartan Potassium | 63 | 22 |
| Glimepiride | Glimepiride | 60 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Carvedilol | Carvedilol | 54 | 13 |
| Tramadol Hcl | Tramadol Hcl | 54 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 22 |
| Donepezil Hcl | Donepezil Hcl | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 11 |
| Sertraline Hcl | Sertraline Hcl | 47 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | 14 |
| Atenolol | Atenolol | 33 | 11 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 14 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Azithromycin | Azithromycin | 29 | 25 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Nystatin | Nystatin | 28 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 23 |
| Prednisone | Prednisone | 24 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Glyburide | Glyburide | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 11 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 16 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Eliquis | Apixaban | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $201.63 · 12 records | Esperion Therapeutics, Inc. | CAPLYTA, ELIQUIS, FANAPT, JARDIANCE, NEXLETOL, NURTEC ODT, Ohtuvayre, Ozempic, SHINGRIX, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error